nb70CAR-T

nb70CAR-T is a type of chimeric antigen receptor (CAR) T cell therapy, an autologous cell therapy in which a patient’s own T cells are genetically modified to express a CAR targeting a specific cell surface antigen associated with cancer. The "nb70" component of the name refers to a specific single-domain antibody fragment (nanobody) engineered to recognize and bind a particular tumor antigen, although the precise antigen targeted by nb70CAR-T is not explicitly specified in public sources as of August 2025. The therapy is expected to function by reprogramming T cells to recognize and kill cancer cells expressing the chosen antigen. CAR-T therapies are typically developed for hematologic malignancies or solid tumors and are considered highly personalized immunotherapies. Mechanistic details can include costimulatory domains such as CD28 or 4-1BB, and a CD3ζ signaling domain to promote T cell activation, proliferation, and cytotoxicity upon engagement with the antigen[1][3][6][7].

Other names

nb70CAR-Tnb-70CAR-Tnb 70CAR-T